EMA Recommendation for the Pediatric Indications of Plerixafor (Mozobil) to Enhance Mobilization of Hematopoietic Stem Cells for Collection and Subsequent Autologous Transplantation in Children with Lymphoma or Malignant Solid Tumors.

The Oncologist
Dominik KarresFrancesco Pignatti

Abstract

On March 28, 2019, the Committee for Medicinal Products for Human Use adopted a positive opinion recommending the marketing authorization for the medicinal product plerixafor. The marketing authorization holder for this medicinal product is Genzyme Europe B.Th. The adoption was for an extension of the existing adult indication in combination with granulocyte colony-stimulating factor (G-CSF) to pediatric patients (aged 1 year to <18 years) to enhance mobilization of hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in children with lymphoma or solid malignant tumors. This treatment is indicated either preemptively, when circulating stem cell count on the predicted day of collection after adequate mobilization with G-CSF (with or without chemotherapy) is expected to be insufficient with regard to desired hematopoietic stem cells yield, or in children who previously failed to collect sufficient hematopoietic stem cells. The efficacy and safety of plerixafor were evaluated in an open label, multicenter, phase I/II, dose-ranging, and randomized controlled study (DFI12860) in pediatric patients with solid tumors, including neuroblastoma, sarcoma, Ewing sarcoma, or lymphoma, who...Continue Reading

References

Jan 5, 2000·The Journal of Clinical Investigation·D Y JoM A Moore
Oct 13, 2000·Science·T Xie, A C Spradling
Apr 6, 2001·The Journal of Immunology : Official Journal of the American Association of Immunologists·H ShenD T Scadden
May 8, 2002·The Journal of Experimental Medicine·Douglas E WrightIrving L Weissman
Aug 18, 2004·Science·Kent W ChristophersonHal E Broxmeyer
Feb 24, 2006·Nature Reviews. Immunology·Anne Wilson, Andreas Trumpp
Mar 22, 2006·Nature Immunology·Gregor B Adams, David T Scadden
Apr 8, 2016·Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis·Serdar SivginAli Unal

❮ Previous
Next ❯

Citations

Feb 16, 2021·Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis·Iwona MalinowskaBozenna Baginska-Dembowska
Jun 24, 2021·Vox Sanguinis·Iñigo RomonMiquel Lozano

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.